Post-earnings recap
Reported
Mon, May 8, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
CRISPR Therapeutics reported a narrower-than-expected loss per share, which surprised analysts positively. The stock reacted modestly, rising by 0.3%, likely due to the company's progress in clinical trials. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.67 | N/A | +59.86% |
| Revenue | N/A | N/A | N/A |
Management expressed cautious optimism about the company's ongoing projects. They noted significant advancements in clinical trials, which could influence future performance.
Management highlighted progress in their clinical trials.
They emphasized the importance of upcoming data releases.
The team remains focused on advancing their pipeline.